Agenix : Riesen Potential - 500 Beiträge pro Seite

[SOM.you.]

RE: Agenix ( vormals Biotech International )

Agenix hat zwei vielversprechende Allianzen geschlossen.

1.) mit Kendle (Nasdaq: KNDL)

Sydney-based biotechnology company Agenix Limited (ASX:AGX) today
announced that its wholly owned subsidiary AGEN Biomedical Limited
had signed an agreement with Nasdaq-listed Kendle International Inc
(Nasdaq: KNDL), to provide services in relation to design and
management of the preclinical and clinical development program for
the company`s revolutionary blood clot imaging technology,
Thromboview(TM). The Phase I trial for Thromboview(TM) will begin
next year. Thromboview(TM) is expected to contribute substantial
revenues and profits to Agenix upon commercialisation

2.) mit Adgene International

ydney-based biotechnology company Agenix Limited (ASX:AGX) -
formerly Biotech International Limited -today announced the signing
of a memorandum of understanding with Singapore-based Hestonville Pte
Ltd (soon to be renamed Adgene International Pte Ltd and or other
name to be approved by the Registrar of Companies).

Adgene International is the Singaporean arm of Shenyang Xiehe Group,
a major biotechnology company based in Shenyang in China.

Under the memorandum, Agenix will provide consulting services and in
return will be issued 7% of the total issued share capital of Adgene
which intends to have raised not less than S$4.0 million. Further,
Agenix will also have the option to invest in any of Adgene`s
projects at any stage of development

Adgene`s business objectives are to promote research and development
initiatives in life sciences and therapeutic products and to realise
revenue from the licensing of intellectual properties. The Xiehe
Group has agreed to transfer its intellectual property in four
ongoing research programs to Adgene.

The projects will be located in Singapore in view of the Singapore
Governments support for such projects.

[/url]



Die Weichen für die Zukunft sind gestellt.
Ein sehr interessanter Wert.





SOM

[SOM.you.]

RE: Agenix


hier weitere Infos dazu :

Shares outstanding : 150 Mio.
Share price : 0,34 AUD
MKap : 51,0 Mio AUD
Gewinn 99/2000: 3,4 Mio AUD
KGV 99/00 : 14,5

Biotech International ist gegliedert in 3 Bereiche :
a) AGEN Biomedical
b) Biotechpharamceuticals
c) Industrial Biosystems / Molecular Products

Umsatzverteilung :
a) 55 %
b) 45 %
c) 5 %

Das letzte halbe Jahr war bei Biotech Intl. in erster Linie durch Zukäufe und Kapitalerhöhungen geprägt.
Unter anderem stieg das Bankhaus UBS bei Biotech Intl (BII) ein.

BII kaufte von Procter und Gamble die MILTON INFANT HYGIENE.
BII stieg mit 31 % bei der PHYTOPROTEIN BIOTECH ein
BII erhöhte den Anteil an der eigenen BIOTECH PHARMACEUTICALS auf 90 %

Trotz erhöhter Forschungsausgaben konnte im ersten halben Jahr das Vorsteuerrgebnis auf dem Vorjahresniveau gehalten werden.

Durch die getätigten Akquisitionen und Forschungserfolge des in der Testphase befindlichen THROMBOVIEW(TM)
hat BII erhebliches Potential in den nächsten Jahren sowohl den Umsatz als auch den Gewinn signifikant zu steigern.
Der Vorstand rechnet mit einer möglichen Umsatzver - 10 - fachung. Das ist aber Zukunftsmusik ab 2003.

Die Pordukte SimpliRED und Dimertest befinden sich auch im Vertrieb auf dem deutschen Markt, und werden darüberhinaus weltweit vertrieben. Es handelt sich um einen Standardtest der 100 % Tochter AGEN . Jeder der schoneinmal Thrombosebeschwerden hatte , konnte möglicherweise durchdiesen Schnelltest eine Diagnose erhalten haben.
Aus Vertriebskreisen war zu erfahren, daß der Test sowohl von niedergelassenen Ärzten, als auch von Krankenhäusern im Europäischen Raum stark nachgefragt wird.

Durch die Zukäufe und das zweistellige organische Wachstum ist mit einer deutlichen Ergebnis und Umsatzsteigerung zu rechnen.

Für das lfd. Jahr rechnet der Vorstand mit einer weiteren Ergebnisverbesserung.

Persönlich halte ich das Investment in Biotech International
für sehr interessant und lukrativ. Ein KGV von 14,5 und ein
zweistelliges jährliches Umsatzwachstum sollten den Aktienkurs mittelfristig beflügeln.

Interessierte Käufer sollten größere Aktienpakete nur in Sydney kaufen ( Stockkürzel : BII.ax Handelsplatz : AAS )
Kleiner Pakete werden auch in Deutschland an der Börse Berlin unter der WKN 936 435 gehandelt.

Als persönliches Kursziel halte ich 0,45 Euro auf 9-15 Monatssicht für realistisch.

Kurs aktuell : 0,17 Euro
Kurziel : 0,45 Euro


SOM


ohne Anspruch auf Richtigkeit, nach bestem Gewissen.
Quellen :

http://www.corbettresearch.com/
http://www.agen.com.au
http://www.haemochrom.de
http://www.biopool.com/
http://www.quicken.com.au
http://www.stockhouse.com.au/

[SOM.you.]

Der Chart ist wohl der bessere aus Sydney :

[SOM.you.]

RE: Agenix

es geht weiter, Das Nasdaq Listing !!

YEES !

+++++++++++++++++++++++++
Blood clot-diagnostic and medical imaging development company Agenix
Limited (ASX:AGX) today announced it had appointed GTH Capital, Inc
of New York to establish an American Depository Receipt program for
the company and to advise it in relation to a listing an NASDAQ.

Mr Don Home, recently appointed CEO of Agenix, said the program would
open up important US capital markets for the company. "A NASDAQ
listing will enable us to trade seamlessly in the US market and will
lead Agenix, and its world class technology, to be revalued on
international terms."

Mr Mark Saunders, executive vice president of GTH Capital, said:
"Agenix is a firm candidate for a NASDAQ listing. The company has
good sales in the North American market and its blue-sky-blood clot
detection product Thromboview - has been extensively tested at the
University of California in San Diego. The company`s product pipeline
and global IP suggest that it will be attractive to US capital
markets and US Investors."

Agenix expects the process to be completed within 12 months.

For more information:



SOM

[SOM.you.]

RE: Agenix

KGV 2000/2001 des abgelaufenen Geschäftsjahres : 8

EPS : 3,12 cents
Kurs : 25 cents (aktuell)
Wachstum : 22 %


Biotechnology company Agenix Limited [ASX:AGX] today announced a 22%
increase in annual net profit to $4.2 million for the year to the end
of June 2001.

Revenue from ordinary activities rose 8% to $29.4 million.

Total assets were $44 million, up 33%, and total liabilities were
$9.7 million, down 16%. Total equity was 58% higher at $34.4 million.
Cash at the end of the year was $3.5 million, up $3.0 million. Profit
before tax increased from $0.4 million to $3.8 million. Earnings per
share increased from 2.96 cents to 3.12 cents, up 5.4%. On a diluted
basis EPS increased from 2.67 cents to 3.12 cents, up 17%.


SOM

[SOM.you.]

RE: Agenix

Agenix meldet einen sagenhaften Anstieg von 55 % beim Umsatz !

AGENIX LIMITED 2001-10-23 ASX-SIGNAL-G

HOMEX - Brisbane

+++++++++++++++++++++++++
Biotechnology company Agenix Limited [ASX:AGX] today announced a 55%
increase in first-quarter revenue to $7.6 million. The revenue for
the corresponding period last year was $4.9 million

Revenue from human and veterinary diagnostic test kit manufacturer
AGEN was $3.2 million for the quarter - 35% higher than the
corresponding quarter last year. This growth figure for the quarter
is double last year`s full-year growth figure.

The first-quarter results follow a 22% increase in annual net profit
to $4.2 million for the financial year to the end of June 2001.

The increase in revenue during the past quarter was due to: growth in
the company`s base business; the introduction of new products from
AGEN; and approximately two months` contribution from Milton
Pharmaceuticals` recently launched expanded Milton product range.
This range has been accepted and is currently in the large
supermarket chains of Woolworths and Coles as well as other smaller
supermarket and pharmaceutical chains.

"This first-quarter performance is in line with the increase
foreshadowed in the shareholders` newsletter distributed in early
September," said Agenix CEO Don Home. "It supports management`s
strategy of focusing on current businesses to maximise returns on
existing products together with the introduction of new products."

As previously indicated the increased profitability will be invested
in the Thromboview(TM) program. Thromboview(TM) is a blood clot
radioimaging antibody reagent, which uses radiolabelled antibodies to
locate blood clots in the body. Phase 1 human trials are due to
commence on the project in 2002.

"The first quarter results follow what was an excellent 2001 year for
Agenix," said Mr Home. "The past year was a turning point for Agenix
as we focused our efforts on growing profits from our existing
businesses and strategically investing, providing the base from which
we will enter a new phase of growth."

"We have a seasonal business where the second half of the
year exceeds the first half associated with our increasing sales
internationally. Given this strong first quarter result the
indications are that we are on target to again achieve double-digit
growth for the full year," said Agenix Chief Financial Officer Jeff
Carter.

For more information:

Don Home, CEO Agenix Limited 07 3370 6396
Jeff Carter, CFO Agenix Limited 02 8875 7898

www.agenix.net



SOM

[SOM.you.]

RE: Agenix

die Aktie befindet sich jetzt
seit einigen Wochen im Aufwärtstrend.


SOM

[SOM.you.]

RE: AGENIX WKN 936435

die Aktie ist weiterhin schön im Aufwärtstrend .

aktuell bei 0,51 AUD
also rund 0,30 Euro

Handelsplatz Berlin und Sydney.







SOM

[SOM.you.]

RE: Agenix AdHoc

Agenix ist mit dem neuen Produkt Thromboview schon so weit fortgeschritten, daß eine Anwendung beim Menschen in diesem Jahr noch erfolgen soll. Aktuell gehts zwar noch um Phase I,
jedoch rechnet man mit einem jährlichen Weltweiten Umsatzpotential von 700 Mio US$.




In the last week Agenix has
received wide media coverage for its lead blood clot detection
product "Thromboview(TM)". This product is aimed at the worldwide
market which is estimated at US$700 million a year. In December
Agenix released a Shareholders` Newsletter regarding a report by KPMG
titled "Commercial Evaluation of Thromboview(TM)"(1). Agenix stated
that Phase 1 clinical trials would commence in 2002. We expect to
begin testing Thromboview(TM) on people later this year.


SOM

[SOM.you.]

RE: agenix

der Kurs in Sydney stabilisiert sich weiter auf hohem Niveau.




SOM

[SOM.you.]

RE: Agenix

Hilfe : Das Halbjahresergebnis war Exellent.

Der Nachsteuergewinn stieg um 435 % im ersten Halbejahr !

RECORD CONTRIBUTION FROM DIAGNOSTIC SUBSIDIARY AGEN

Biotechnology company Agenix Limited (ASX: AGX] today announced a
435% increase in after-tax profit to $1.7 million for the six months
to December 31, 2001.

This compares to a profit of $0.3 million for the corresponding
six-month period to December 2000.


Umsatzanstieg um 66 % Gewinn anstieg um 435 %

Key group financials for the period were:

2001 (6 MTHS) 2000(6 MTHS) % INCREASE

Group Sales $18.8 million $11.3 million 66%
Agen $9.5 million $6.1 Million 55%
Milton $9.0 million $5.0 million 80%
Jemaka $0.3 million $0.2 million 52%
Operating Profit $1.9 million $0.5 million 272%
Tax $0.2 million $0.2 million -
Net Profit $1.7 million $0.3 million 435%
EBITDAR $3.7 million $2.3 million 59%
EPS 1.1 cents $0.3 cents 270%

Ein wirklich geiles Ergebnis.

SOM